PCP
SUPN icon

Perimeter Capital Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Perimeter Capital Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-26,427
Closed -$230K – 36
2014
Q3 		$230K Sell
26,427
-123,632
-82% -$1.12M 0.39% 73
2014
Q2 		$1.64M Sell
150,059
-6,396
-4% -$57K 0.84% 24
2014
Q1 		$1.4M Buy
+156,455
New +$1.44M 0.7% 67

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MOACM
Mutual of America Capital Management New York $10.3B AUM 43.46% 1-Year Est. Return

Perimeter Capital Partners's SUPN Position: Q4 2014 in Review

Perimeter Capital Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2014, closing a stake of 26,427 shares — an estimated $230K sold.

Perimeter Capital Partners first reported a position in SUPN in Q1 2014 and held it in 3 quarters. The position peaked at $1.64M in Q2 2014. 107 funds tracked by Wall St. Rank hold SUPN as of Q4 2014.

  • Perimeter Capital Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Perimeter Capital Partners sold 26,427 Supernus Pharmaceuticals shares in Q4 2014, an estimated $230K.
  • Perimeter Capital Partners first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Perimeter Capital Partners's Supernus Pharmaceuticals position peaked at $1.64M in Q2 2014.
  • 107 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2014.

Based on Perimeter Capital Partners's 13F filing for Q4 2014.